For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

  1. Link

    fgfr3-antibody-epr23043-ab133644.pdf

  1. Send me a copy of this email
    I agree to the terms and conditions.
Cardiovascular Angiogenesis Growth Factors FGF FGF Receptors
Share by email
Validated using a knockout cell lineRecombinantRabMAb

Recombinant Anti-FGFR3 antibody [EPR2304(3)] (ab133644)

  • Datasheet
  • SDS
Reviews (2)Q&A (3)References (11)

Product price, shipping and contact information

Currently unavailable

Sorry, we can't display this right now.

Please contact us to place your order, or try again later.

 

Loading size & price…

 

Shipping and order information

Shipping info

Promotion Information

Abpromise

Guaranteed product quality, expert customer support.

Find out more.

Western blot - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
  • Western blot - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
  • OI-RD Scanning - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
  • Anti-FGFR3 antibody [EPR2304(3)] (ab133644)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR2304(3)] to FGFR3
  • Suitable for: WB
  • Knockout validated
  • Reacts with: Human

Conjugates logo Related conjugates and formulations

Carrier Free

You may also be interested in

Secondary
Product image
Goat Anti-Rabbit IgG H&L (HRP) (ab205718)
Knockout
Product image
Human FGFR3 knockout HEK-293 cell lysate (ab259781)
Protein
Product image
Recombinant human FGFR3 protein (ab60857)

View more associated products

Overview

  • Product name

    Anti-FGFR3 antibody [EPR2304(3)]
    See all FGFR3 primary antibodies
  • Description

    Rabbit monoclonal [EPR2304(3)] to FGFR3
  • Host species

    Rabbit
  • Specificity

    We have tested this antibody in positive Mouse and Rat tissue lysates in WB and could not obtain a specific band for FGFR3. Please get in touch with our Scientific Support team if you wish to share any data regarding this antibody’s cross-reactivity in Mouse and Rat species.

  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF or IHC-P
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human FGFR3 aa 1-100 (extracellular). The exact sequence is proprietary.
    Database link: P22607
    (Peptide available as ab195871)

  • Positive control

    • WB: K562, HepG2 and HEK293 lysates.
  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
  • Dissociation constant (KD)

    KD = 1.62 x 10 -11 M
    Learn more about KD
  • Storage buffer

    pH: 7.20
    Preservative: 0.01% Sodium azide
    Constituents: 59% PBS, 0.05% BSA, 40% Glycerol
  • Concentration information loading...
  • Purity

    Protein A purified
  • Clonality

    Monoclonal
  • Clone number

    EPR2304(3)
  • Isotype

    IgG
  • Research areas

    • Cardiovascular
    • Angiogenesis
    • Growth Factors
    • FGF
    • FGF Receptors
    • Signal Transduction
    • Growth Factors/Hormones
    • FGF
    • Cancer
    • Growth factors
    • FGF
    • Stem Cells
    • Neural Stem Cells
    • Glial Restricted Lineage
    • Astrocyte
    • Neuroscience
    • Development
    • Neuroscience
    • Processes

Associated products

  • Alternative Versions

    • Anti-FGFR3 antibody [EPR2304(3)] - BSA and Azide free (ab187341)
  • Compatible Secondaries

    • Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077)
    • Goat Anti-Rabbit IgG H&L (HRP) (ab205718)
  • Immunizing Peptide (Blocking)

    • Human FGFR3 peptide (ab195871)
  • Isotype control

    • Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730)
  • KO cell lines

    • Human FGFR3 knockout HEK-293 cell line (ab259775)
  • KO cell lysates

    • Human FGFR3 knockout HEK-293 cell lysate (ab259781)
  • Positive Controls

    • HeLa whole cell lysate (ab29545)
    • HeLa membrane extract lysate (ab29547)
    • Mouse brain tissue lysate - total protein (0 days) (ab7188)
    • Mouse brain tissue lysate - total protein (14 days) (ab7189)
    • Mouse brain tissue lysate - total protein (7 days) (ab7190)
    • A549 whole cell lysate (ab7910)
    • K-562 whole cell lysate (ab7911)
  • Recombinant Protein

    • Recombinant human FGFR3 protein (ab60857)

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab133644 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB (1)
1/1000 - 1/2000. Predicted molecular weight: 88 kDa.Can be blocked with Human FGFR3 peptide (ab195871).

Abcam recommends to block in 3% non-fat milk.

Notes
WB
1/1000 - 1/2000. Predicted molecular weight: 88 kDa.Can be blocked with Human FGFR3 peptide (ab195871).

Abcam recommends to block in 3% non-fat milk.

Application notes
Is unsuitable for Flow Cyt,ICC/IF or IHC-P.

Target

  • Function

    Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1.
  • Tissue specificity

    Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Isoform 2 is detected in epithelial cells. Isoform 1 is not detected in epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic cells.
  • Involvement in disease

    Defects in FGFR3 are the cause of achondroplasia (ACH) [MIM:100800]. ACH is an autosomal dominant disease and is the most frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands.
    Defects in FGFR3 are the cause of Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]. Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independent disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosomal dominant mode of inheritance.
    Defects in FGFR3 are a cause of thanatophoric dysplasia type (TD) [MIM:187600, 187601]; also known as thanatophoric dwarfism or platyspondylic lethal skeletal dysplasia Sand Diego type (PLSD-SD). TD is the most common neonatal lethal skeletal dysplasia. Affected individuals display features similar to those seen in homozygous achondroplasia. It causes severe shortening of the limbs with macrocephaly, narrow thorax and short ribs. In the most common subtype, TD1, femur are curved, while in TD2, straight femurs are associated with cloverleaf skull. Mutations affecting different functional domains of FGFR3 cause different forms of this lethal disorder.
    Defects in FGFR3 are a cause of hypochondroplasia (HCH) [MIM:146000]. HCH is an autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.
    Defects in FGFR3 are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Somatic mutations can constitutively activate FGFR3.
    Defects in FGFR3 are a cause of cervical cancer (CERCA) [MIM:603956]. A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.
    Defects in FGFR3 are the cause of camptodactyly tall stature and hearing loss syndrome (CATSHL syndrome) [MIM:610474]. CATSHL syndrome is an autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or mental retardation, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.
    Defects in FGFR3 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving FGFR3 is found in multiple myeloma. Translocation t(4;14)(p16.3;q32.3) with the IgH locus.
    Defects in FGFR3 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.
    Defects in FGFR3 are a cause of keratinocytic non-epidermolytic nevus (KNEN) [MIM:162900]; also known as pigmented moles. Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.
    Defects in FGFR3 are a cause of Muenke syndrome (MNKS) [MIM:602849]; also known as Muenke non-syndromic coronal craniosynostosis. MNKS is a condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, mental retardation and respiratory insufficiency.
    Defects in FGFR3 are a cause of keratosis seborrheic (KERSEB) [MIM:182000]. A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.
  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Cellular localization

    Membrane.
  • Target information above from: UniProt accession P22607 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links

    • Entrez Gene: 2261 Human
    • Omim: 134934 Human
    • SwissProt: P22607 Human
    • Unigene: 1420 Human
    • Alternative names

      • ACH antibody
      • CD 333 antibody
      • CD333 antibody
      • CD333 antigen antibody
      • CEK 2 antibody
      • CEK2 antibody
      • FGFR 3 antibody
      • FGFR-3 antibody
      • FGFR3 antibody
      • FGFR3_HUMAN antibody
      • Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarfism) antibody
      • Fibroblast growth factor receptor 3 antibody
      • Heparin binding growth factor receptor antibody
      • HSFGFR3EX antibody
      • Hydroxyaryl protein kinase antibody
      • JTK 4 antibody
      • JTK4 antibody
      • MFR 3 antibody
      • SAM 3 antibody
      • Tyrosine kinase JTK 4 antibody
      • Tyrosine kinase JTK4 antibody
      • Z FGFR 3 antibody
      see all

    Images

    • Western blot - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
      Western blot - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
      All lanes : Anti-FGFR3 antibody [EPR2304(3)] (ab133644) at 1/2000 dilution

      Lane 1 : HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysates
      Lane 2 : K-562 (Human chronic myelogenous leukemia lymphoblast) whole cell lysates
      Lane 3 : MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysates
      Lane 4 : IM-9 (Human multiple myeloma B Lymphoblast) whole cell lysates

      Lysates/proteins at 20 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20000 dilution

      Predicted band size: 88 kDa



      Blocking/Diluting buffer and concentration: 5% NFDM/TBST

    • Western blot - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
      Western blot - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
      All lanes : Anti-FGFR3 antibody [EPR2304(3)] (ab133644) at 1/1000 dilution

      Lane 1 : Wild-type HEK-293 whole cell lysate
      Lane 2 : FGFR3 knockout HEK-293 whole cell lysate
      Lane 3 : HepG2 whole cell lysate

      Lysates/proteins at 20 µg per lane.

      Predicted band size: 88 kDa
      Observed band size: 125 kDa why is the actual band size different from the predicted?



      Lanes 1 - 3: Merged signal (red and green). Green - ab133644 observed at 125kDa. Red - loading control, ab9484, observed at 37 kDa.

      ab133644 was shown to recognize in wild-type HEK-293 cells as signal was lost at the expected MW in FGFR3 knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and FGFR3 knockout samples were subjected to SDS-PAGE. Ab133644 and ab9484 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.

    • OI-RD Scanning - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
      OI-RD Scanning - Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
      Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD
    • Anti-FGFR3 antibody [EPR2304(3)] (ab133644)
      Anti-FGFR3 antibody [EPR2304(3)] (ab133644)

    Protocols

    • Western blot protocols

    Click here to view the general protocols

    Datasheets and documents

    • SDS download

    • Datasheet download

      Download

    References (11)

    Publishing research using ab133644? Please let us know so that we can cite the reference in this datasheet.

    ab133644 has been referenced in 11 publications.

    • Wang Q  et al. MicroRNA-124-3p inhibits the differentiation of precartilaginous stem cells into nucleus pulposus-like cells via targeting FSTL1. Exp Ther Med 22:725 (2021). PubMed: 34007334
    • Liu PCC  et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One 15:e0231877 (2020). PubMed: 32315352
    • Zhou BY  et al. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. Acta Pharmacol Sin 41:1234-1245 (2020). PubMed: 32327724
    • Barrows D  et al. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer. Proc Natl Acad Sci U S A 117:25732-25741 (2020). PubMed: 32989154
    • Yu D  et al. Dual roles of misshapen/NIK-related kinase (MINK1) in osteoarthritis subtypes through the activation of TGFß signaling. Osteoarthritis Cartilage 28:112-121 (2020). PubMed: 31647983
    View all Publications for this product

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    1-5 of 5 Abreviews or Q&A

    Flow Cytometry abreview for Anti-FGFR3 antibody [EPR2304(3)]

    Excellent
    Abreviews
    Abreviews
    This product is known to not work in this application or species.
    abreview image
    Application
    Flow Cytometry
    Sample
    Human Cell (Head and Neck cancer line)
    Permeabilization
    No
    Gating Strategy
    Singlets in Viable cells
    Specification
    Head and Neck cancer line
    Preparation
    Cell harvesting/tissue preparation method: Cells were detached by EDTA
    Sample buffer: 2% FBS in PBS
    Fixation
    No fix
    Read More

    Abcam user community

    Verified customer

    Submitted Jan 20 2016

    Western blot abreview for Anti-FGFR3 antibody [EPR2304(3)]

    Excellent
    Abreviews
    Abreviews
    abreview image
    Application
    Western blot
    Sample
    Human Cell lysate - whole cell (tumor lysate)
    Gel Running Conditions
    Reduced Denaturing (4-20% gel)
    Loading amount
    25 µg
    Specification
    tumor lysate
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 25°C
    Read More

    Abcam user community

    Verified customer

    Submitted Jan 20 2016

    Question

    I received FGFR3 antibody(ab133644) today. I am wondering how to dilute it.  Would you please give me some suggestions?

    Read More

    Abcam community

    Verified customer

    Asked on Jul 12 2013

    Answer

    In Western blot this antibody can be diluted in incubation buffers such as 3% nonfat dry milk/TBS. We recommend using this antibody at a concetration range between 1/1000-1/10,000.

    Read More

    Keith B

    Abcam Scientific Support

    Answered on Jul 12 2013

    Question

    Dear Technical Support,   Would you happen to know what the concentration of this antibody is? The datasheet for this antibody and the labeling on the tube does not specify this information.   Appreciate your help.  

    Read More

    Abcam community

    Verified customer

    Asked on Nov 09 2012

    Answer

    Thank you for your enquiry.

    I can confirm that ab133644 Anti-FGFR3 antibody is sold as tissue culture supernatant. Unpurified antibodies, such as those sold as whole antiserum, ascites or tissue culture supernatant will not have a concentration stated on the datasheet. Antibody concentration is usually determined by protein assay, and tissue culture supernatant will contain a lot of other proteins, which means the antibody quantification would not be accurate.

    I can confirm that for tissue culture supernatant, concentration of antibody is known to very between 1 - 3 mg/ml

    I am sorry we are not able to provide an exact concentration on this occasion, but hope this information will be helpful to you. If you have any further questions, please do not hesitate to contact us.

    Read More

    Abcam Scientific Support

    Answered on Nov 09 2012

    Question

    Product code: 53636
    Inquiry: Ab53636: is this antibody also available without predilution (we would like to test the specifity in western blot)

    Read More

    Abcam community

    Verified customer

    Asked on Jul 03 2012

    Answer

    Thank you for your enquiry and your interest.

    I can confirm that ab53636 has been manufactured and designed as a prediluted (ready to use) antibody for Immunohistochemistry.

    We have several alternative antibodies against the same target - FGFR3 - which have been tested for Western blot application such as ab10651, ab133644, ab10649, ab64190, ab89660, ab52247. You may wish to take a look at the on-line datasheets of these products.

    If you need any further assistance in the future, please do not hesitate to contact me.

    Read More

    Abcam Scientific Support

    Answered on Jul 03 2012

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Get resources and offers direct to your inbox Sign up
    A-Z by research area
    • Cancer
    • Cardiovascular
    • Cell biology
    • Developmental biology
    • Epigenetics & Nuclear signaling
    • Immunology
    • Metabolism
    • Microbiology
    • Neuroscience
    • Signal transduction
    • Stem cells
    A-Z by product type
    • Primary antibodies
    • Secondary antibodies
    • Biochemicals
    • Isotype controls
    • Flow cytometry multi-color selector
    • Kits
    • Loading controls
    • Lysates
    • Peptides
    • Proteins
    • Slides
    • Tags and cell markers
    • Tools & Reagents
    Help & support
    • Support
    • Make an Inquiry
    • Protocols & troubleshooting
    • Placing an order
    • RabMAb products
    • Biochemical product FAQs
    • Training
    • Browse by Target
    Company
    • Corporate site
    • Investor relations
    • Company news
    • Careers
    • About us
    • Blog
    Events
    • Tradeshows
    • Conferences
    International websites
    • abcam.cn
    • abcam.co.jp

    Join with us

    • LinkedIn
    • facebook
    • Twitter
    • YouTube
    • Terms of sale
    • Website terms of use
    • Cookie policy
    • Privacy policy
    • Legal
    • Modern slavery statement
    © 1998-2022 Abcam plc. All rights reserved.